AbbVie has submitted an application to the European Medicines Agency (EMA) for approval of SKYRIZI (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This follows positive results from the Phase 3 AFFIRM study, which showed the drug's efficacy and safety. If approved, patients will have the option to receive induction doses via subcutaneous injection in addition to the existing intravenous method, potentially improving treatment convenience. SKYRIZI is already approved for Crohn's disease and other immune-related conditions in the EU and US.
Investing in three blue-chip dividend stocks—Altria, AbbVie, and Chevron—each paying dividends quarterly on different schedules, can create a monthly income stream throughout the year. Altria pays in January, April, July, and October with a high yiel...
With inflation expected to remain high, five Dividend Aristocrats—companies with 25+ years of rising dividends—are recommended for investors seeking stable income and growth. These firms, including AbbVie, Chevron, PepsiCo, Procter & Gamble, and Targ...
AbbVie continues to demonstrate solid revenue and earnings growth driven by the strong performance of Skyrizi and Rinvoq, which compensate for declines in Humira sales. Recent regulatory approvals and expanded market opportunities support the company...
